Location of Repository

Suppression of HBV by Tenofovir in HBV/HIV coinfected patients : a systematic review and meta-analysis

By Huw Price, David Dunn, Deenan Pillay, Firouze Bani-Sadr, Theodora de Vries-Sluijs, Mamta K. Jain, Noriyoshi Kuzushita, Stefan Mauss, Marina Núñez, Reto Nüesch, Marion Peters, Thomas Reiberger, Christoph Stephan, Lionel Tan and Richard Gilson

Abstract

Background: Hepatitis B coinfection is common in HIV-positive individuals and as antiretroviral therapy has made death due to AIDS less common, hepatitis has become increasingly important. Several drugs are available to treat hepatitis B. The most potent and the one with the lowest risk of resistance appears to be tenofovir (TDF). However there are several questions that remain unanswered regarding the use of TDF, including the proportion of patients that achieves suppression of HBV viral load and over what time, whether suppression is durable and whether prior treatment with other HBV-active drugs such as lamivudine, compromises the efficacy of TDF due to possible selection of resistant HBV strains.\ud Methods: A systematic review and meta-analysis following PRISMA guidelines and using multilevel mixed effects logistic regression, stratified by prior and/or concomitant use of lamivudine and/or emtricitabine.\ud Results: Data was available from 23 studies including 550 HBV/HIV coinfected patients treated with TDF. Follow up was for up to seven years but to ensure sufficient power the data analyses were limited to three years. The overall proportion achieving suppression of HBV replication was 57.4%, 79.0% and 85.6% at one, two and three years, respectively. No effect of prior or concomitant 3TC/FTC was shown. Virological rebound on TDF treatment was rare.\ud Interpretation: TDF suppresses HBV to undetectable levels in the majority of HBV/HIV coinfected patients with the proportion fully suppressed continuing to increase during continuous treatment. Prior treatment with 3TC/FTC does not compromise efficacy of TDF treatment. The use of combination treatment with 3TC/FTC offers no significant benefit over TDF alone

Topics: ddc:610
Year: 2013
OAI identifier: oai:publikationen.ub.uni-frankfurt.de:31132

Suggested articles

Preview

Citations

  1. (2006). A 48-week Study of Tenofovir or Lamivudine or a Combination of Tenofovir and Lamivudine for the Treatment of Chronic Hepatitis B in HIV/HBV-co-infected
  2. (2008). A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naive individuals in Thailand.
  3. (2010). British HIV Association guidelines for the management of coinfection with HIV-1 and hepatitis B or C virus
  4. (2010). Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues.
  5. (2006). Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection.
  6. (2004). Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection.
  7. (2008). Comparison of the antiviral activity of adefovir and tenofovir on hepatitis B virus in HIVHBV-coinfected patients.
  8. Delaney WEt (2007) In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents.
  9. (2006). Effect of switching to tenofovir with emtricitabine in patients with chronic hepatitis B failing to respond to an adefovir-containing regimen.
  10. (2011). Efficacy and tolerance of a combination of tenofovir disoproxil fumarate plus emtricitabine in patients with chronic hepatitis B: a European multicenter study.
  11. (2004). Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus.
  12. (2010). Efficacy of tenofovir disoproxil fumarate/emtricitabine compared with emtricitabine alone in antiretroviral-naive HIV-HBV coinfection in Thailand.
  13. (2012). Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study.
  14. (2008). Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV.
  15. (2012). Five-year on-treatment efficacy of lamivudine-, tenofovir- and tenofovir+emtricitabine-based HAART in HBV–HIV-coinfected patients.
  16. (2004). Funnel plots in meta-analysis.
  17. (2012). Hepatitis B Surface Antigen Decline and Clearance During Long-Term Tenofovir Therapy in Patients Coinfected With HBV and HIV.
  18. (2005). Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort coinfected with human immunodeficiency virus.
  19. (2008). Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection.
  20. (2006). Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus.
  21. (2006). Liverrelated deaths in persons infected with the human immunodeficiency virus: the D:A:D study.
  22. (2010). Long-term efficacy of lamivudine/emtricitabine and tenofovir combination therapy on HBV/HIV co-infected Japanese patients. 61st Annual Meeting of the American Association for the Study of Liver Diseases.
  23. (1999). Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients.
  24. (2009). Long-term outcome of tenofovir disoproxil fumarate use against hepatitis B in an HIV-coinfected cohort.
  25. (2003). Long-term tenofovir treatment of lamivudine-resistant chronic
  26. (2010). Long-term Therapy With Tenofovir Is Effective for Patients Co-Infected With Human Immunodeficiency Virus and Hepatitis B Virus.
  27. (2009). Longer duration of HBV-active antiretroviral Therapy is linked to favorable virological outcome in HIV-HBV co-infected patients.
  28. (2011). Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir.
  29. (2004). Ninety-six-week efficacy of combination therapy with lamivudine and tenofovir in patients coinfected with HIV-1 and wild-type hepatitis B virus.
  30. (2010). Predictors of loss of hepatitis B surface antigen in HIV-infected patients.
  31. (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
  32. (2008). Prior lamivudine (Lam) failure may delay time to complete HBV-DNA suppression in HIV patients treated with tenofovir plus Lam. 59th Annual Meeting of the American Association for the Study of Liver Diseases.
  33. (2006). Randomized controlled study of tenofovir and adefovir
  34. (2009). Reduced glomerular filtration rate but sustained virologic response in HIV/hepatitis B coinfected individuals on long-term tenofovir.
  35. (2005). Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir.
  36. (2009). Tenofovir (TDF) is effective in lamivudine (LAM)-resistant chronic hepatitis B patients who harbor rtA194T at baseline. 60th Annual Meeting of the American Association for the Study of Liver Diseases.
  37. (2010). Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses.
  38. (2008). Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
  39. (2010). Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronichepatitis B virus infection.
  40. (2008). Tenofovir-based rescue therapy for advanced liver disease in 6 patients coinfected with HIV and hepatitis B virus and receiving lamivudine.
  41. (2009). The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains.
  42. (2007). Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response.
  43. (2011). Virologic Outcome of Using Tenofovir/Emtricitabine to Treat Hepatitis B in HIV-Coinfected Patients.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.